Related Experiment Videos
Summary
This study identified key serum enzymes for distinguishing benign and malignant ovarian tumors. Alkaline ribonuclease (RNase) combined with aspartyl (AspAT) or alanyl (AlAT) aminotransferases showed the best diagnostic potential.
Area of Science:
- Biochemistry
- Oncology
- Clinical Diagnostics
Background:
- Ovarian tumors present a diagnostic challenge.
- Biomarkers are crucial for early detection and differentiation of benign and malignant ovarian neoplasms.
Purpose of the Study:
- To evaluate the efficacy of various serum enzymatic activities as potential biomarkers for differentiating benign and malignant ovarian tumors.
- To identify the most effective enzyme combinations for diagnostic purposes.
Main Methods:
- Serum samples from patients with benign and malignant ovarian tumors were analyzed before treatment.
- Enzymatic activities including alkaline and acid phosphatases, aspartyl (AspAT) and alanyl (AlAT) aminotransferases, leucyl (LAP) and alanyl (AAP) aminopeptidases, lactate dehydrogenase (LDH), gamma-glutamyl transpeptidase, cathepsin, alkaline ribonuclease (RNase), and beta-glucuronidase were measured.
Main Results:
- Alkaline and acid phosphatases, along with leucyl aminopeptidase (LAP), showed limited utility in discriminating between benign and malignant ovarian tumors.
- Combinations such as alkaline ribonuclease (RNase) with aspartyl (AspAT) or alanyl (AlAT) aminotransferases, and RNase with alanyl aminopeptidase (AAP) and lactate dehydrogenase (LDH) demonstrated significant potential as effective marker enzymes.
Conclusions:
- Certain serum enzymatic activities, particularly RNase in combination with AspAT/AlAT or AAP/LDH, can serve as valuable markers for differentiating ovarian tumors.
- Specific enzyme panels offer improved diagnostic accuracy compared to individual enzyme measurements.